Optimal Clinical Effect of Sandostatin LAR Treatment for Gastroenteropancreatic (GEP) Carcinoid

#1149

Introduction: The incidence of carcinoid is 2/100 000 with a consistent trend grow due to improved diagnosis of these tumors in recent years. There are two peaks of carcinoid incidence – the first between the 15th and 25th years and the second–between the 65th and 75th years

Aim(s): This clinical case is about 65 year old lady with carcinoid of ileum operated in 1990 stage T2N0M0. Omental and hepatal metastases of the same tumor with increased level of Chromogranin A and expressed flush syndrome were diagnosed in this patient 10 years later.

Materials and methods: Surgery treatment was not considered in this patient due to disease extension, therapy with Sandostatin LAR was indicated and was performed since 1999. Treatment monitoring was carried out by CT studies, serum level of Chromogranin A assessment, and recently using SPECT-CT somatostatin-receptor scintigraphy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Robev B, Sergieva S,

Keywords: Carcinoid, Sandostatin LAR,

To read the full abstract, please log into your ENETS Member account.